News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Pozen, Inc. Reports Third Quarter 2006 Results
October 31, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
POZEN reported a net loss of $4.1 million, or $0.14 per share on a diluted basis, for the third quarter of 2006, compared to a net loss of $4.7 million, or $0.16 per share on a diluted basis, for the third quarter of 2005.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
China
Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+
September 5, 2025
·
2 min read
·
Tristan Manalac
Layoffs
AC Immune Downsizes by 30%, Narrows Pipeline Focus
September 4, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment
September 3, 2025
·
2 min read
·
Tristan Manalac
Deals
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact
September 2, 2025
·
2 min read
·
Heather McKenzie